Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879805 | 0.82 | TAAR1 (0.48) | TAAR1RIPK1KDM4ECYP3A4MAPT | |
| SCHEMBL31265560 | 0.82 | SLC6A4 (0.57) | TAAR1KDM4ECYP3A4MAPTSLC6A4 | |
| SCHEMBL8016874 | 0.82 | SLC6A4 (0.57) | TAAR1KDM4ECYP3A4MAPTSLC6A4 | |
| SCHEMBL6910479 | 0.80 | TAAR1 (0.47) | TAAR1RIPK1KDM4ECYP3A4MAPT | |
| SCHEMBL19233952 | 0.79 | TAAR1 (0.46) | TAAR1KDM4ECYP3A4MAPTSLC6A4 | |
| SCHEMBL14630026 | 0.77 | RIPK1 (0.49) | TAAR1RIPK1IDO1KDM1ASLC6A4 | |
| SCHEMBL3056754 | 0.77 | TAAR1 (1.00) | TAAR1IDO1KDM4EKMT2ATSHR | |
| SCHEMBL8703610 | 0.76 | TAAR1 (0.64) | TAAR1CYP2A13IDO1TSHRALDH1A1 | |
| SCHEMBL29930048 | 0.76 | TAAR1 (0.64) | TAAR1CYP2A13IDO1TSHRALDH1A1 | |
| SCHEMBL11194513 | 0.76 | KMT2A (0.47) | TAAR1RIPK1CYP2A13IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737453-A1 | NOVEL SELENOPHENE DERIVATIVES | Aigen Sciences Inc. (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025005748-A1 | NOVEL SELENOPHENE DERIVATIVES | (주)아이젠사이언스 | 2025-01-02 | — | — | WO | disclosed |
| CN-115135315-B | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-1448187-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040029940-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-12 | — | — | US | disclosed |
| WO-2004000788-A1 | UREIDO-SUBSTITUTED ANILINE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000214-A2 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| US-6596747-B2 | For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH) | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| WO-2003047512-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0871653-B1 | NOVEL AMINO ACID DERIVATIVES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOUNDS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| US-6232468-B1 | ANTIINFLAMMATORY AGENT | BOEHRINGER INGELHEIM KG (DE) | 2001-05-15 | — | — | US | disclosed |
| EP-0871653-A1 | NOVEL AMINO ACID DERIVATIVES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOUNDS CONTAINING THESE COMPOUNDS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 1998-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | TAAR1 4531/4885RIPK1 1927/4885CYP2A13 4373/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | TAAR1 4552/4885RIPK1 1301/4885CYP2A13 4756/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | TAAR1 4603/4885RIPK1 1317/4885CYP2A13 4722/4885 |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | IMPDH1, IMPDH2, IMPA1 | TAAR1 2587/4885RIPK1 3609/4885CYP2A13 461/4885 |
| US-20040029940-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | F7, F8, F13B | TAAR1 766/4885RIPK1 4871/4885CYP2A13 1081/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | TAAR1 4552/4885RIPK1 1301/4885CYP2A13 4756/4885 |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | TAAR1 3556/4885RIPK1 468/4885CYP2A13 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.